TY  - JOUR
AU  - Zijlstra, Josée M
AU  - Follows, George
AU  - Casasnovas, Rene-Olivier
AU  - Vermaat, Joost S P
AU  - Kalakonda, Nagesh
AU  - Choquet, Sylvain
AU  - Hill, Brian
AU  - Thieblemont, Catherine
AU  - Cavallo, Federica
AU  - Cruz, Fatima De la
AU  - Kuruvilla, John
AU  - Hamad, Nada
AU  - Jaeger, Ulrich
AU  - Caimi, Paolo
AU  - Gurion, Ronit
AU  - Warzocha, Krzysztof
AU  - Bakhshi, Sameer
AU  - Sancho, Juan-Manuel
AU  - Schuster, Michael
AU  - Egyed, Miklos
AU  - Offner, Fritz
AU  - Vassilakopoulos, Theodoros P
AU  - Samal, Priyanka
AU  - Ku, Matthew
AU  - Xu, Jenny
AU  - Corona, Kelly
AU  - Chamoun, Kamal
AU  - Shah, Jatin
AU  - Canales, Miguel
AU  - Maerevoet, Marie
PY  - 2022
DO  - 10.3390/cancers14030791
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/20872
T2  - Cancers
AB  - Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc analyses, we analyzed...
LA  - en
KW  - SADAL study
KW  - diffuse large B-cell lymphoma
KW  - exportin 1
KW  - selinexor
TI  - The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
TY  - research article
VL  - 14
ER  -